Stock CYC CYCLOPHARM LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cyclopharm Limited

Equities

CYC

AU000000CYC5

Advanced Medical Equipment & Technology

Market Closed - Australian S.E.
Other stock markets
 08:02:08 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.75 AUD 0.00% Intraday chart for Cyclopharm Limited -1.69% -9.09%
Mar. 19 Cyclopharm's Technegas Device Carries Out Imaging of First US Patients MT
Mar. 18 Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 92.32 200.7 153.1 108.9 181.1 164.8 - -
Enterprise Value (EV) 1 84.58 198.8 128.4 108.9 181.1 164.8 164.8 164.8
P/E ratio -29.4 x -30.7 x -29.2 x -16.2 x -39.5 x -69.7 x 14.3 x 7.42 x
Yield 0.79% 0.4% 0.61% - - 0.57% 3.5% 6.77%
Capitalization / Revenue 6.56 x 13.7 x 8.65 x 4.69 x 6.88 x 4.41 x 2.71 x 2.04 x
EV / Revenue 6.56 x 13.7 x 8.65 x 4.69 x 6.88 x 4.41 x 2.71 x 2.04 x
EV / EBITDA -80.6 x -42.5 x -43.8 x -22.5 x -23.8 x -183 x 10.9 x 5.97 x
EV / FCF -95.5 x -21.2 x -61.9 x - - -26.6 x 13.5 x 7.96 x
FCF Yield -1.05% -4.72% -1.61% - - -3.76% 7.4% 12.6%
Price to Book 4.24 x 12 x 3.57 x - - 5.57 x 4.11 x 2.91 x
Nbr of stocks (in thousands) 78,238 80,274 93,375 93,054 94,096 94,190 - -
Reference price 2 0.8261 1.922 1.189 0.7971 1.311 1.141 1.141 1.141
Announcement Date 2/26/20 2/25/21 2/23/22 2/20/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 14.08 14.68 17.7 23.22 26.34 37.4 60.9 80.7
EBITDA 1 -1.145 -4.726 -3.499 -4.832 -7.611 -0.9 15.1 27.6
EBIT 1 -2.145 -5.636 -4.258 -5.764 -8.55 -2 14 26.1
Operating Margin -15.23% -38.39% -24.05% -24.82% -32.46% -5.35% 22.99% 32.34%
Earnings before Tax (EBT) 1 -2.425 -5.844 -4.347 -6.03 -4.19 -2.3 13.8 25.9
Net income 1 -2.912 -6.044 -5.04 -6.612 -4.701 -2.3 11.5 22.2
Net margin -20.69% -41.17% -28.47% -28.47% -17.85% -6.15% 18.88% 27.51%
EPS 2 -0.0281 -0.0625 -0.0407 -0.0491 -0.0332 -0.0164 0.0799 0.1539
Free Cash Flow 1 -0.9666 -9.466 -2.472 - - -6.2 12.2 20.7
FCF margin -6.87% -64.48% -13.96% - - -16.58% 20.03% 25.65%
FCF Conversion (EBITDA) - - - - - - 80.79% 75%
FCF Conversion (Net income) - - - - - - 106.09% 93.24%
Dividend per Share 2 0.006560 0.007640 0.007240 - - 0.006550 0.0400 0.0773
Announcement Date 2/26/20 2/25/21 2/23/22 2/20/23 2/27/24 - - -
1AUD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 - 10.62 16.5 20.9
EBITDA 1 - -5.527 -1.5 0.6
EBIT 1 - -6 -2 -0.1
Operating Margin - -56.52% -12.12% -0.48%
Earnings before Tax (EBT) - - - -
Net income -2.895 - - -
Net margin - - - -
EPS -0.0202 - - -
Dividend per Share - - - -
Announcement Date 8/22/23 2/27/24 - -
1AUD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 7.74 1.87 24.7 - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -0.97 -9.47 -2.47 - - -6.2 12.2 20.7
ROE (net income / shareholders' equity) -14.5% -30% -16.7% - - -7% 35.4% 46.7%
ROA (Net income/ Total Assets) -10.4% - - - - - - -
Assets 1 28.03 - - - - - - -
Book Value Per Share 2 0.1900 0.1600 0.3300 - - 0.2000 0.2800 0.3900
Cash Flow per Share - - - - - - - -
Capex 0.04 0.19 0.84 - - - - -
Capex / Sales 0.27% 1.32% 4.76% - - - - -
Announcement Date 2/26/20 2/25/21 2/23/22 2/20/23 2/27/24 - - -
1AUD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Cyclopharm Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.141 USD
Average target price
3.004 USD
Spread / Average Target
+163.22%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
CYCLOPHARM LIMITED Stock Cyclopharm Limited
-9.09% 107M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. CYC Stock
  4. Financials Cyclopharm Limited